The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from the outside.
What I am trying to establish is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.
Numbers rather than impressions, if you have them.
mark_tokyo said:The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…
Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:
| Feature | Platform A | Platform B | Platform C |
|---|---|---|---|
| Initial Consult | $75 | $95 | $0 |
| Monthly Follow-up | $45 | Included | $60 |
| Prescription Speed | Same day | 24-48 hours | Same day |
| Lab Monitoring | Required | Optional | Required |
I settled on the one that required labs — it shows they care about safety, not just prescribing volume.
InsuranceTom said:Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription.
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemmark_tokyo said:The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…
Same experience, arrived at from the opposite direction. Nothing to add that would improve it.
Clinical perspective, offered as context rather than as advice.
mark_tokyo said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.